US 12,168,052 B2
Nant COVID vaccine cross reactivity
Patrick Soon-Shiong, Culver City, CA (US)
Assigned to ImmunityBio, Inc., Culver City, CA (US)
Filed by ImmunityBio, Inc., Culver City, CA (US)
Filed on Mar. 28, 2024, as Appl. No. 18/620,192.
Application 18/620,192 is a continuation of application No. 18/533,042, filed on Dec. 7, 2023, granted, now 12,016,916.
Application 18/533,042 is a continuation of application No. 18/060,513, filed on Nov. 30, 2022, granted, now 11,911,459, issued on Feb. 27, 2024.
Claims priority of provisional application 63/284,203, filed on Nov. 30, 2021.
Prior Publication US 2024/0226282 A1, Jul. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/215 (2006.01); A61K 39/00 (2006.01); A61P 31/14 (2006.01)
CPC A61K 39/215 (2013.01) [A61P 31/14 (2018.01); A61K 2039/545 (2013.01); A61K 2039/572 (2013.01)] 16 Claims
 
1. A vaccine composition for eliciting in a subject an immune response against SARS-COV-2 or a variant thereof, the composition comprising
1) a first vaccine for administration as a prime vaccination, the first vaccine comprising an RNA vaccine comprising a ribonucleic acid encoding a severe acute respiratory syndrome (SARS) coronavirus spike protein (S), and
2) a second vaccine for administration as a boost vaccination, the second vaccine comprising a recombinant adenovirus comprising a first and second nucleic acid, wherein the first nucleic acid encodes a SARS coronavirus nucleocapsid protein (N) that is fused to an endosomal targeting sequence (N-ETSD), wherein the first nucleic acid encodes the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO:7; and wherein the second nucleic acid encodes a SARS coronavirus spike protein (S).